We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cambridge Major Laboratories and AAIPharma Services Announce Merger


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cambridge Major Laboratories and AAIPharma Services Announce Merger"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. have announced their intent to merge to form the premier global supplier of integrated CMC services. Financial terms of the merger were not disclosed.

The merger is expected to close by the end of October 2013, subject to Hart-Scott-Rodino approval and other closing conditions. “The basis for the merger was to start with the right building blocks – a merger of two equals: two highly respected, market-leading firms with proven expertise in API development, analytical chemistry, and finished dosage forms,” said Brian Scanlan, CEO & President of CML. “We believe that we have a strong foundation to deliver superior customer-oriented solutions to expedite drug development and commercialization.”

Scanlan added, “Joining forces to offer a full suite of integrated CMC services delivers meaningful value to customers and the ability to execute with equal strength across API development, analytical services, and finished dosage form manufacturing. The combined CML and AAIPharma will provide a superior customer experience defined by high-quality facilities, best-in-class capabilities, scientific expertise, geographic proximity, and effective support services that maximize scientific and project interaction at each phase.”

”The merger of these two organizations will offer customers a reliable partner that can address the majority of their pharmaceutical development and manufacturing requirements,” stated Patrick Walsh, CEO of AAIPharma Services.

Walsh continued, “The combined organization will provide comprehensive services that include process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid and sterile), packaging, and stability services, all supported by robust project management.”

Advertisement